Hidrocortisona (Hydrocortisone)

Hydrocortisone injectable is indicated for several acute and chronic conditions that require rapid systemic glucocorticoid activity.

• Adrenal insufficiency and secondary adrenal failure, particularly in patients with pituitary or hypothalamic dysfunction.
• Acute adrenal crisis requiring immediate cortisol replacement to prevent circulatory collapse.
• Septic shock as adjunctive therapy to support vascular tone and reduce inflammatory mediators.
• Severe allergic or anaphylactic reactions unresponsive to epinephrine alone, where rapid anti‑inflammatory action is needed.
• Systemic inflammatory disorders such as vasculitis, lupus flare, or severe asthma exacerbation that require high‑dose corticosteroid control.
• Peri‑operative stress dosing for patients on chronic corticosteroid therapy to prevent adrenal crisis during surgery.

• Hydrocortisone binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. The activated complex up‑regulates anti‑inflammatory proteins such as annexin‑1 and down‑regulates pro‑inflammatory cytokines (e.g., IL‑1, IL‑6, TNF‑α). It also influences carbohydrate, protein, and lipid metabolism, increasing gluconeogenesis and reducing capillary permeability, thereby producing systemic anti‑inflammatory and immunosuppressive effects and contributes to stress‑response adaptation.

Hydrocortisone may cause a range of adverse reactions, varying from mild and transient to potentially life‑threatening.

Common

• Injection site pain, erythema, or swelling that usually resolves within hours.
• Transient hyperglycemia, especially in diabetic patients, which may require temporary adjustment of glucose‑lowering therapy.
• Mild electrolyte disturbances such as modest sodium retention and potassium loss, often self‑limited.
• Fluid retention leading to mild weight gain or peripheral edema, typically managed with monitoring.

Serious

• Severe infection or sepsis due to immunosuppression, which may necessitate antimicrobial therapy and close monitoring.
• Acute adrenal suppression on abrupt discontinuation, presenting as hypotension, fatigue, or electrolyte imbalance.
• Psychiatric disturbances including mood swings, psychosis, insomnia, or depression, requiring psychiatric evaluation.

When prescribing hydrocortisone injectable, clinicians should evaluate patient history and monitor for conditions that may increase risk of complications.

• Assess for active or latent infections before initiating therapy.
• Use the lowest effective dose for the shortest duration to limit systemic effects.
• Monitor blood glucose levels in diabetic or pre‑diabetic patients.
• Observe electrolytes, especially sodium and potassium, during prolonged treatment.
• Evaluate for signs of adrenal suppression when tapering or discontinuing.
• Consider contraindication in patients with known hypersensitivity to hydrocortisone or formulation excipients.
• Use caution in pregnant or breastfeeding women, as safety data are limited.

Hydrocortisone can alter the pharmacokinetics or pharmacodynamics of several co‑administered agents; awareness of key interactions helps prevent adverse outcomes.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may markedly reduce hydrocortisone exposure.
• Co‑administration with systemic anticoagulants (e.g., warfarin) without monitoring, as glucocorticoids can affect coagulation parameters.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – increased risk of gastrointestinal ulceration.
• Vaccines, especially live attenuated vaccines – immunosuppression may diminish vaccine efficacy.
• Diabetic medications – hydrocortisone may raise blood glucose, requiring dose adjustment.
• Antihypertensive agents – fluid retention can blunt antihypertensive effect.